McKesson MCK Business Segments
| FY'26 | FY'25 | FY'24 | FY'23 | ||
|---|---|---|---|---|---|
| Total revenues by Business | |||||
| Medical-Surgical Solutions | $11.51B+1.1% | $11.38B+0.7% | $11.31B+1.8% | $11.11B-4.3% | |
| North American Pharmaceutical | $336.65B+10.6% | $304.51B+16.5% | $261.37B— | —— | |
| Oncology & Multispecialty | $48.42B+31.4% | $36.86B+20.9% | $30.49B— | —— | |
| Prescription Technology Solutions | $5.81B+11.3% | $5.22B+9.4% | $4.77B+8.7% | $4.39B+13.5% | |
| Total long-lived assets by Geography | |||||
| Foreign | $1.1B— | —— | —— | —— | |
| United States | $12.35B— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does McKesson break its business down?
- McKesson (MCK) reports total revenues by business across 4 parts — Medical-Surgical Solutions, North American Pharmaceutical, Oncology & Multispecialty and Prescription Technology Solutions. Each is extracted from the segment footnotes and tracked over time.
- Where does McKesson's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in McKesson's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
